Ovarian cancer typically responds well to initial platinum-based chemotherapy treatment. However, most tumors subsequently relapse and eventually become resistant, for which the prognosis is poor and no therapeutic options which have shown substantial OS benefit. Futher, the available chemotherapies are associated with significant adverse effects that negatively impact quality of life for the patient. Emerging therapies with novel mechanisms of action and adverse effect profiles, such as folate receptor alpha-targeting antibody-drug conjugates (FR ADCs), will be required for effective management of platinum-resistant ovarian cancer. In this CE Concepts Snack, expert faculty will address critical gaps in clinician knowledge and competence by equipping learners with strategies to categorize treatment options and optimize patient-specific care plans incorporating novel therapies. Faculty will also explore approaches to mitigating disparities in ovarian cancer care, ensuring learners can implement equitable, evidence-based practices that enhance patient outcomes.
- Provider:Creative Educational Concepts, Inc.
- Activity Link: https://www.ceconcepts.com/
- Start Date: 2025-01-31 06:00:00
- End Date: 2025-01-31 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine, Medical Oncology